Study of AK146D1 and AK112 for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced non-small cell lung cancer (stage IIIB/IIIC or IV) that cannot be cured by surgery or standard chemo-radiation.
- You must be in good enough physical condition to be up and about (ECOG score 0 or 1).
- You must have at least one measurable tumor outside the brain.
- You must not have had previous treatment targeting the Trop2 or Nectin4 proteins or topoisomerase I inhibitors.
- You must not have active or untreated brain metastases, unless they are stable after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
This trial tests a new immunotherapy drug, AK112, for people with a specific type of lung cancer (non-squamous) that has certain genetic changes and has stopped responding to targeted therapy. The goal is to see if AK112 can help when targeted treatments no longer work.
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
This trial tests a new drug, AK112, combined with chemotherapy for people with non-squamous non-small cell lung cancer that has spread to the brain and does not have certain genetic changes. The goal is to see if this combination is safe and effective as the first treatment.
This trial tests a new drug, AK112, combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer that has spread to the lining of the lung (malignant pleural effusion). The goal is to see if this combination helps shrink tumors and improve outcomes.
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
Hear when a new Advanced Non Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.